Acknowledgments
We thank INOVA, Thermo-Fisher and BioRad for performing the assays.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: XB has received speaker fees from Thermo Fisher and Inova, has been a consultant for Inova and has received a research grant from Thermo Fisher. EC has received lecture fees from Bio-Rad Lab, Inova Diagnostics and Thermo Fisher.
Employment or leadership: MM and CB are employed by Inova Diagnostics.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Damoiseaux J, Csernok E, Rasmussen N, Moosig F, van Paasen P, Baslund B, et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicenter European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. Ann Rheum Dis 2016;76:647–53.10.1136/annrheumdis-2016-209507Search in Google Scholar PubMed
2. Mahler M, Bogdanos DP, Pavlidis P, Fritzler MJ, Csernok E, Damoiseaux J, et al. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. Clin Chim Acta 2013;424:267–73.10.1016/j.cca.2013.06.005Search in Google Scholar PubMed
3. Arias-Loste MT, Bonilla G, Moraleja I, Mahler M, Mieses MA, Castro B, et al. Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease. Clin Rev Allergy Immunol 2013;45:109–16.10.1007/s12016-012-8349-4Search in Google Scholar PubMed
4. Bossuyt X: Serologic markers in inflammatory bowel disease. Clin Chem 2006;52:171–81.10.1373/clinchem.2005.058560Search in Google Scholar PubMed
5. Joossens S, Daperno M, Shums Z, Van SK, Goeken JA, Trapani C, et al. Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitis. Clin Chem 2004;50:1422–5.10.1373/clinchem.2004.032318Search in Google Scholar PubMed
6. Sy A, Khalidi N, Dehghan N, Barra L, Carette S, Cuthbertson D, et al. Vasculitis Clinical Research Consortium (VCRC); Canadian Vasculitis Network (CanVasc). Vasculitis in patients with inflammatory bowel diseases: a study of 32 patients and systematic review of the literature. Semin Arthritis Rheum 2016;45:475–82.10.1016/j.semarthrit.2015.07.006Search in Google Scholar PubMed PubMed Central
7. Humbert S, Guilpain P, Puéchal X, Terrier B, Rivière S, Mahr A, et al. French Vasculitis Study Group. Inflammatory bowel diseases in anti-neutrophil cytoplasmic antibody-associated vasculitides: 11 retrospective cases from the French Vasculitis Study Group. Rheumatology (Oxford) 2015;54:1970–5.10.1093/rheumatology/kev199Search in Google Scholar PubMed
8. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2–6.10.3109/00365528909091339Search in Google Scholar PubMed
9. Sowa M, Grossmann K, Knütter I, Hiemann R, Röber N, Anderer U, et al. Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA. PLoS One 2014;9:e107743.10.1371/journal.pone.0107743Search in Google Scholar PubMed PubMed Central
©2018 Walter de Gruyter GmbH, Berlin/Boston
